Mycenax Biotech (4726) reported revenue of NT$98 million for Oct 2026, +41.0% year on year and -15.8% from the previous month. Revenue for Jan–Oct 2026 was NT$806.1 million (+53.5% year on year).
Year-on-year revenue growth: 4 months in a row. →
In Oct 2026, it ranked No. 75 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$98 million | +41.0% | -15.8% |
| Sep 2026 | NT$116.4 million | +393.3% | +9.9% |
| Aug 2026 | NT$105.9 million | +131.4% | +23.1% |
| Jul 2026 | NT$86 million | +38.6% | +59.6% |
| Jun 2026 | NT$53.8 million | -48.9% | +26.7% |
| May 2026 | NT$42.5 million | -39.7% | -60.2% |
| Apr 2026 | NT$106.7 million | +301.0% | +12.9% |
| Mar 2026 | NT$94.6 million | +78.6% | +67.1% |
| Feb 2026 | NT$56.6 million | +140.4% | +23.9% |
| Jan 2026 | NT$45.7 million | +0.9% | -64.1% |
| Dec 2025 | NT$127.3 million | +156.4% | +45.0% |
| Nov 2025 | NT$87.8 million | -19.5% | +26.3% |
| Oct 2025 | NT$69.5 million | +97.1% | +194.6% |
| Sep 2025 | NT$23.6 million | -60.6% | -48.4% |
| Aug 2025 | NT$45.7 million | -33.8% | -26.3% |
| Jul 2025 | NT$62 million | -22.5% | -41.1% |
| Jun 2025 | NT$105.4 million | +20.3% | +49.4% |
| May 2025 | NT$70.5 million | +18.4% | +165.0% |
| Apr 2025 | NT$26.6 million | -50.1% | -49.7% |
| Mar 2025 | NT$52.9 million | +28.1% | +125.0% |
| Feb 2025 | NT$23.5 million | -0.3% | -48.0% |
| Jan 2025 | NT$45.2 million | +196.5% | -8.9% |
| Dec 2024 | NT$49.7 million | -34.2% | -54.5% |
| Nov 2024 | NT$109.1 million | +150.6% | +209.3% |
| Oct 2024 | NT$35.3 million | -44.8% | -41.2% |
Jan–Oct 2026 cumulative: NT$806.1 million (+53.5% YoY)
Other Biotech & Medical companies
Compare with peers: Mycenax Biotech vs PEC / Mycenax Biotech vs Lotus Pharm / Mycenax Biotech vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本公司以提供CDMO技術服務為主,收入係以滿足履約義務時認列,本月累計完成履約義務較去年累計增加。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16